IMPACT BIOMEDICAL INC.

For the period ended Dec 31, 2025. Filed Mar 11, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 11, 2026

IBO$4.33+5.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

	For the Year Ended December 31,
2025 · 2024
Revenue:
Biotech retail sales	$32,000	$	-
Total revenue	32,000		-
Costs and expenses:
Cost of revenue	424,000		-
Sales, general and administrative compensation (inclusive of stock-based compensation)	873,000		718,000
Sales and marketing	24,000		633,000
Professional Fees	1,005,000		446,000
Research and development	340,000		278,000
Depreciation and Amortization	1,145,000		1,119,000
Rent and utilities	74,000		32,000
Impairment of goodwill	-		25,093,000
Impairment of fixed assets	-		263,000
Loss on disposal of fixed assets	12,000		-
Other operating expenses	417,000		171,000
Total costs and expenses	4,314,000		28,753,000
Operating loss	(4,282,000)		(28,753,000)
Other income (expense):
Interest income	13,000		13,000
Change in fair value of note payable, related party	(9,388,000)		5,068,000
Interest expense	(793,000)		(1,065,000)
Loss from operations before income taxes	(14,450,000)		(24,737,000)
Income tax benefit (expense)	2,580,000		(33,000)
Net loss	$(11,870,000)		$(24,770,000)
Loss from operations attributed to noncontrolling interest	32,000		62,000
Net loss attributable to common stockholders	$(11,838,000)		$(24,708,000)
Earnings per common share:
Basic	$(0.38)		$(2.30)
Diluted	$(0.38)		$(2.30)
Shares used in computing loss per common share:
Basic	31,550,457		10,757,147
Diluted	31,550,457		10,757,147

**I

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.